Abbott India Q1 FY27: Profit up 17%, margin expands

Key update from the June-quarter filing

Abbott India Ltd reported a 17.12% year-on-year rise in consolidated net profit for the first quarter of FY27, supported by a sharp improvement in operating profitability. The drug maker posted profit after tax of ₹429 crore for the quarter ended June 30, 2026, compared with ₹366 crore in the year-ago period. While revenue growth was modest, EBITDA rose at a faster pace, pushing margins higher.

The company had also informed the BSE that its board meeting was scheduled for August 12, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The results update and the formal board approval process were key points tracked by investors given Abbott India’s premium valuation and sensitivity to margin trends.

Q1 FY27 numbers: profit grows faster than sales

Consolidated revenue for Q1 FY27 came in at ₹1,813.6 crore, up 4.3% year-on-year from ₹1,738.4 crore. Consolidated EBITDA increased 17.3% to ₹522.4 crore versus ₹445.5 crore in Q1 FY26. The faster growth in EBITDA compared with revenue translated into a visible margin expansion.

Abbott India’s EBITDA margin expanded to 28.81% in Q1 FY27 from 25.63% in Q1 FY26. The margin move stands out because the revenue increase was in low single digits, indicating that operating performance rather than top-line acceleration drove most of the quarter’s improvement.

Margin expansion is the main signal in this quarter

The quarter’s margin expansion is a central takeaway for investors following Abbott India’s earnings quality. A rise from 25.63% to 28.81% implies a stronger operating surplus per rupee of sales in the June quarter. This, in turn, supported the double-digit growth in net profit despite revenue increasing at a slower pace.

The company also reported EBITDA of ₹522.4 crore, which provides a clearer picture of operational profitability before depreciation, interest and taxes. With net profit at ₹429 crore, the quarter suggests that operating performance translated effectively into the bottom line.

Board meeting and disclosures to stock exchanges

Abbott India informed BSE that the meeting of the Board of Directors was scheduled on 12/08/2026. The agenda included considering and approving the unaudited financial results for the quarter ended June 30, 2026. Such board meeting intimations are a standard part of compliance for listed companies and typically coincide with results finalisation.

The same data set also referenced a “trading window closed till August 14”, in the context of the board meeting timeline. Investors generally watch these timelines because they indicate the formal window around which price-sensitive information is expected to be published.

Quick snapshot: Q1 FY27 vs year-ago and previous quarter

The article text included “Quick Details” such as the results date, the quarter under review, and the immediate prior quarter’s revenue and profit figures. These figures help place the Q1 FY27 print in both a year-on-year and quarter-on-quarter context, even if the headline comparisons are primarily year-on-year.

What the quarter suggests when viewed against recent trend

The previous quarter figures in the provided text show revenue of ₹1,709.51 crore and PAT of ₹394.93 crore. Against that, Q1 FY27 revenue at ₹1,813.6 crore indicates a higher sales base than the immediately preceding quarter, while PAT at ₹429 crore is also higher than the prior quarter’s ₹394.93 crore based on the “Quick Details” data.

At the same time, the previous quarter EBITDA margin was listed at 32%, which is higher than Q1 FY27’s 28.81%. That comparison highlights that margin can vary meaningfully quarter to quarter, even in periods where year-on-year margin expands.

Longer-view financial context from annual profit and EBITDA data

The article text also included a multi-year Profit & Loss table with annual EBITDA and reported PAT figures. While this does not provide Q1 seasonality details, it offers a broad view of operating profit and profit after tax over multiple years.

The annual series shows both EBITDA and reported PAT rising across the period shown. For investors, such tables are typically used to gauge consistency in profitability and the longer-run trajectory of earnings, while quarterly results determine near-term performance.

Market impact: what investors can take from the numbers

The market-facing indicators in the provided text include the closing market price (CMP) of ₹27,835.0 and the key profitability metrics. In this update, the most material operational shift is the year-on-year margin expansion to 28.81%. The company’s profit growth of 17.12% year-on-year is also significantly ahead of the 4.3% revenue growth.

Because the board meeting and results date were clearly stated as August 12, 2026, investors tracking the stock around that date would typically focus on the confirmed financial numbers and any accompanying statutory filings or publication of unaudited results.

Analysis: why this quarter matters

Q1 FY27 stands out for Abbott India due to the divergence between revenue growth and profit growth. With revenue up 4.3% but EBITDA up 17.3%, the operating leverage implied by the numbers becomes the focal point. The EBITDA margin move from 25.63% to 28.81% is large enough to explain much of the profit outperformance.

The “Quick Details” section also provides a practical benchmark against the previous quarter, where the EBITDA margin was listed at 32%. That contrast suggests that while year-on-year profitability improved, the quarter still sits below the margin level reported for the immediately prior period in the dataset.

Conclusion

Abbott India’s Q1 FY27 results show net profit rising to ₹429 crore and revenue increasing to ₹1,813.6 crore, with EBITDA margin expanding to 28.81%. The company had scheduled its board meeting for August 12, 2026 to consider and approve the unaudited results for the quarter ended June 30, 2026. Going ahead, investors are likely to track subsequent exchange filings and the next quarter’s update to see whether the improved year-on-year margin trend sustains.